| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
• CymaBay Therapeutics, Inc. (NASDAQ:CBAY) shares increased by 144.02% to $4.49 during Tuesday's pre-market session. The most recent rating by Cantor Fitzgerald, on May 12, is at Overweight, with a price target of $15.
• Gamida Cell, Inc. (NASDAQ:GMDA) shares moved upwards by 67.40% to $7.60. The most recent rating by HC Wainwright & Co., on Apr 27, is at Buy, with a price target of $15.
• Helius Medical, Inc. (NASDAQ:HSDT) shares moved upwards by 54.12% to $0.66.
• Novavax, Inc. (NASDAQ:NVAX) stock rose 48.90% to $36.48. The most recent rating by H.C. Wainwright, on May 12, is at Buy, with a price target of $50.
• Akorn, Inc. (NASDAQ:AKRX) shares moved upwards by 45.31% to $0.37.
• Macrogenics, Inc. (NASDAQ:MGNX) stock rose 21.12% to $31.88. The most recent rating by Credit Suisse, on May 6, is at Outperform, with a price target of $13.
• Fluidigm, Inc. (NASDAQ:FLDM) shares rose 12.04% to $5.49.
• Redhill Biopharma, Inc. (NASDAQ:RDHL) shares moved upwards by 10.50% to $8. The most recent rating by H.C. Wainwright, on Mar 5, is at Buy, with a price target of $14.
• Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) shares rose 10.20% to $0.81.
• Guardion Health Sciences, Inc. (NASDAQ:GHSI) stock increased by 10% to $0.55.
• Genfit, Inc. (NASDAQ:GNFT) shares decreased by 65.48% to $7.49 during Tuesday's pre-market session. The most recent rating by SVB Leerink, on May 12, is at Outperform, with a price target of $20.
• Nabriva Therapeutics, Inc. (NASDAQ:NBRV) stock declined 14.93% to $0.62. According to the most recent rating by H.C. Wainwright, on Apr 9, the current rating is at Neutral.
• Marker Therapeutics, Inc. (NASDAQ:MRKR) shares fell 10.08% to $2.23. The most recent rating by Piper Sandler, on May 12, is at Neutral, with a price target of $2.
• DBV Technologies, Inc. (NASDAQ:DBVT) stock decreased by 9.42% to $5.58. The most recent rating by Citigroup, on Apr 6, is at Buy, with a price target of $10.
• Cellect Biotechnology, Inc. (NASDAQ:APOP) shares declined 8.86% to $3.60.
• Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares declined 6.61% to $12. The most recent rating by JP Morgan, on May 6, is at Overweight, with a price target of $18.
• Ra Medical Systems, Inc. (NYSE:RMED) stock declined 5.50% to $1.03. The most recent rating by Cantor Fitzgerald, on Mar 11, is at Neutral, with a price target of $2.
• Tilray, Inc. (NASDAQ:TLRY) stock declined 4.08% to $7.75. The most recent rating by Cantor Fitzgerald, on May 11, is at Neutral, with a price target of $7.
• Cellectis, Inc. (NASDAQ:CLLS) shares fell 3.09% to $14.75. The most recent rating by Goldman Sachs, on Mar 6, is at Sell, with a price target of $11.
• Ocugen, Inc. (NASDAQ:OCGN) shares fell 3.03% to $0.32.
Posted In: AKBA AKRX APOP CBAY CLLS DBVT DFFN FLDM GHSI GMDA GNFT HSDT MGNX MRKR NBRV NVAX OCGN RDHL RMED TLRY
